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surgery in the Dutch health care setting. The hypothesis was that
higher drug costs for the tramadol/paracetamol combination
were offset by a reduction of costs associated with the treatment
of side-effects. METHODS: Decision analysis was used to model
the health economic outcomes. A cost-minimisation approach
was appropriate since the efﬁcacy of the two treatments proved
to be the same in the dosages used. Probabilities, resource utili-
sation data, and unit costs were obtained from published litera-
ture, Delphi panel and ofﬁcial price and tariff lists (Dutch costing
manual). The perspective taken was that of the health insurance.
RESULTS: The study showed that six days’ postoperative treat-
ment with the tramadol/paracetamol combination is cost saving
compared with codeine plus paracetamol and has fewer side-
effects (costs for tramadol/paracetamol: €42.46; codeine/parac-
etamol: €43.56). Sensitivity analyses conﬁrmed the robustness of
the model, with the tramadol/paracetamol combination being
similarly expensive or becoming the dominant strategy in 28 off
34 scenarios calculated. CONCLUSION: The results show that
postoperative pain therapy with the tramadol/paracetamol com-
bination is equally or less expensive and has fewer side effects
compared with a codeine/paracetamol combination, resulting in
favourable clinical and economic beneﬁts.
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OBJECTIVE: NeP pain is a devastating disorder that is likely to
compromise the patient’s quality of life. Generic tools are used
to measure impact of pain on health-related quality of life
(HRQoL) such as SF-12. The goal of this analysis was to assess
the reliability, concurrent and discriminant validity of SF-12 in
NeP or Mixed Pain (MP) patients. METHODS: Horizontal psy-
chometric properties were tested in a sample of 1519, with pain
for 1.1 + 2.8]patients [mean + SD; 56.0 + 13.7 years old (61,2%
female) years enrolled in an observational, prospective and mul-
ticenter study in NeP or MP patients of broad etiologies. Partic-
ipants completed a pain questionnaire (SF-MPQ), anxiety and
depression scales (Covi and Raskin), a disability inventory (SDS)
and the MOS-sleep questionnaire. RESULTS: Most patients
scored above 40mm on the SF-MPQ. Near 92% of patients com-
pleted the questionnaire. Test-retest reliability for both summary
components showed intraclass correlation coefﬁcients ranging
from 0.743 to 0.898 (p < 0.0001 in all cases). SF-12xs PCS was
able to distinguish between Nep and MP patients (adjusted mean
difference: 1.95 + 0.37; p < 0.0001), and levels of pain severity
(adjusted F = 4.91, p = 0.008), and disability (adjusted F = 7.15,
p < 0.0001). SF-12xs MCS showed its validity to differentiate
between patients with and without depression (adjusted mean
difference: 5.05 + 0.74; p < 0.0001). MCS & PCS showed con-
current correlations with anxiety (Covi; -0.21 to -0.43), depres-
sion (Raskin; -0.25 to -0.52), sleep disorders (MOS-sleep; -0.16
to -0.35) and disability (ShDS; -0.02 to -0.27). CONCLU-
SIONS: These results demonstrated the SF-12xs validity and reli-
ability as a measure of HRQoL in NeP patients.
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OBJECTIVE: Pain is associated with an important comorbidity,
related with sleep problems and mood disorders. This study was
aimed to describe the health status of patients according to pain
severity and symptom descriptors among patients with neuro-
pathic (NeP) or nociceptive pain (NoP). METHODS: We sur-
veyed 135 patients with pain (85 NeP and 50 NoP) of broad
origin attending three Pain Units. Patients completed the Short-
Form McGill Pain Questionnaire (SF-MPQ). Health status
(utility) was determined by means of the Health Utility Index
Mark 3 (HUI 3, Spanish version). Present Pain Intensity item
(PPI) of SF-MPQ was used to classiﬁed pain severity as mild, dis-
comforting, distressing, horrible and excruciating, and the 15
items of questionnaire to describe descriptors of pain. A descrip-
tor was considered absent in case of a score of 0, and present if
scoring ranged from 1 to 4. Analysis of covariance models and
multivariate regression were used. RESULTS: Mean (+ sem) age
was 62.6 + 1.3 years (range: 22–88) and 58% were female.
Eighty-seven percent were prescribed pain medications. Most
reported mild (22%), discomforting (36%) or distressing (24%)
pain, with 11% scoring the pain as horrible and 6% excruciat-
ing. Male and NoP patients were associated with poorer adjusted
HUI 3 scores: 0.41 + 0.04 (F = 4.22, p = 0.042) and 0.37 + 0.04
(F = 9.75, p = 0.002), respectively. Adjusted HUI 3 scores were
statistically associated with poorer PPI scoring: 0.66 + 0.05, 0.53
+ 0.04, 0.30 + 0.05, 0.20 + 0.09 and 0.39 + 0.15, respectively
(F = 8.33; p < 0.001). Tiring-exhausting and punishing-cruel
(affective symptoms) were both associated with lower HUI 3
scores: b-coefﬁcients; -0.149 (p = 0.010) and -0.171 (p = 0.005),
respectively. Health status was no associated with sensory symp-
toms descriptors. CONCLUSIONS: Present pain intensity and
presence of affective symptoms were both associated with a
poorer health status; the more severe the pain the more impaired
the health status, and was independent of age. Male and Noci-
ceptive Pain patients showed worst health status.
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OBJECTIVE: This work assessed the psychometric properties 
of the MOS-sleep scale in NeP syndromes. METHODS:
Psychometric properties were tested in NeP patients enrolled in
a naturalistic, prospective, multicenter study exploring the effec-
tiveness of gabapentin for 3 months. Participants completed
scales for pain (SF-McGill Pain Questionnaire), anxiety (Covi),
depression (Raskin), disability (Sheehan), and HRQoL (SF-12).
Feasibility, reliability, validity and sensitivity to change were
measured within this study. RESULTS: Six-hundred-three
patients [58.4 + 14.4 years (65.1% female), mean +, with pain
for 1.2 + 3.3 years were included. Pain intensity in a VAS
scored]SD 0–100 was 70.9 + 19.4 and in an ordinal item 0–5
was 2.8 + 1.1. The 10.9% of patients suffered neuropathies,
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9.6% trigeminal neuralgia, 12.8% CRPS, 14.8% post-herpetic
neuralgia, 19.1% entrapment neuropathies, 3.6% post-stroke
pain, 2.7% phantom limb, and 26.5% others. MOS-sleep was
acceptable (items with missing data <10% and ﬂoor and ceiling
effects <50% per item and <15% per domain) and reliable
(Cronbachxs a between 0.64 and 0.87, and test-retest intraclass
correlation coefﬁcients between 0.79 and 0.91, p < 0.001 for all
cases). After adjusting by covariates, MOS-sleep was able to dis-
tinguish between sex, present pain severity, level of disability and
presence of anxiety or depression: sleep-problems index scores
higher in female and patients with horrible/excruciating pain,
anxiety, depression and extreme disability (p < 0.05, all cases).
Concurrent validity with other scales was moderate; Spearman’s
rho coefﬁcients between -0.21 and 0.57 (p < 0.01, all cases).
MOS-sleep was sensitive to change after treatment with
gabapentin; after adjusting, responders (baseline pain reduction
>50%) showed a reduction in sleep-problems index of -25.6 +
14.3pts versus -12.1 + 14.5pts in non responders (F = 80.5, p
< 0.0001). Scoring reduction in summary index and sleep sub-
scales correlated signiﬁcantly with pain improvement (Pearson 
r-coefﬁcients between 0.428 and 0.116, p < 0.01, all cases).
CONCLUSIONS: MOS-sleep showed good psychometric prop-
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OBJECTIVES: No epidemiological data are available for hyper-
hidrosis (excessive sweating) in the UK, although a 2.9% preva-
lence rate recently was reported in a census-type study in the
USA. A retrospective cohort study was designed to estimate age-
and sex-speciﬁc incidence and prevalence in patients presenting
to UK general practitioners over 1994–2003. Longitudinal
trends including seasonality were examined and patient man-
agement was analysed in terms of prescription, referral and test
rates. METHODS: The UK General Practice Research Database
(GPRD) includes computerised medical records for 3 million
active patients (~5% of UK population) from over 350 practices.
GPRD coding dictionaries were reviewed to compile a list of
hyperhidrosis-related medical codes (HMC) and prescription
codes (HPC). Many HMCs and HPCs are not used exclusively
for hyperhidrosis, so three cohort deﬁnitions were tested to
explore their speciﬁcity and sensitivity. Prevalence was estimated
by assuming that the condition is chronic with no resolution.
RESULTS: In 2003 the estimated incidence of hyperhidrosis was
0.21% (n = 4267) for patients with an HMC, and 0.08% (n =
1598) for patients with an HMC and an HPC. Incidence doubled
over 1994 to 2003; was 1.5 times higher in females than males;
and was 1.4 times higher in summer (Apr–Sept) than winter
(Oct–Mar). Prevalence was estimated at 1.62% (32,406) in
2003. There were 2831 referrals associated with HMCs over
1994–2003, of which 986 were to pathology, 541 to general
medical and only 425 to dermatology. Prescriptions for anti-
perspirants were written for 6324 patients, but only 713 received
more than 5 prescriptions in total over 1994–2003. CONCLU-
SIONS: The GPRD is a useful tool to investigate the epidemiol-
ogy and treatment of hyperhidrosis in the UK. Potential
misclassiﬁcation of cases was explored using different cohort def-
initions. Referral rates by general practitioners were low and rel-
atively few patients persisted with anti-perspirants.
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OBJECTIVES: The aim of this study was to assess the cost-effec-
tiveness of imiquimod cream 5%, in the treatment of superﬁcial
basal cell carcinomas (sBCC) compared to usual care in Norway.
METHODS: The cost-effectiveness analysis was performed
using a decision model, comparing imiquimod, a topical immune
response modiﬁer, with usual care in a Norwegian practice
setting. Estimates of initial clearance and recurrence in sBCC are
from randomized clinical trials of imiquimod and from literature
reviews supplemented by assessments from structured interviews
with clinical dermatologists. RESULTS: Dermatologists reported
the distribution of treatment options for sBCC in Norway as
surgery (30%), cryosurgery (40%) and photodynamic therapy
(30%). A weighted composite outcome of these three alterna-
tives (usual care) was used as basis for the comparison. Adverse
events and their consequences in terms of treatment costs were
considered in the model. The model estimates of initial clearance
with imiquimod compared to usual care in sBCC was 94% vs.
88%. The analysis found imiquimod to be slightly more expen-
sive per patient (NOK133 per year). The incremental cost-effec-
tiveness ratio (ICER) for imiquimod compared to usual care was
NOK1973 per recurrence avoided based on a 1-year time per-
spective. For individual therapy options, imiquimod dominated
PDT, was more expensive but with better outcomes than
cryosurgery, yet was dominated by excision surgery. CONCLU-
SION: The total cost of treatment with imiquimod was margin-
ally higher than the weighted average for usual care, but the
treatment with imiquimod substantially reduced recurrence of
sBCC. Similar to most other measures of effect, there are no
general accepted levels for the societies’ willingness to pay for
avoided recurrences of sBCC; even so, based on this analysis it
is reasonable to conclude that imiquimod provides a cost-
effective treatment option for sBCC in Norway.
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OBJECTIVE: To assess the costs, consequences and cost-effec-
tiveness of Elidel (pimecrolimus cream 1%) in treatment of chil-
dren with atopic dermatitis in Hungary. METHODS: A Markov
model for atopic dermatitis developed by the Erasmus Univer-
sity (Rotterdam, The Netherlands) was adapted to the Hungar-
ian health care settings. The model based on a double-blind,
multicenter, randomized, parallel-group study. Patients were 
randomised (2:1) to receive pimecrolimus treatment paradigm
(i.e. emollients, pimecrolimus, medium potency topical corticos-
teroids) or standard of care (emollients, vehicle, medium potency
topical corticosteroids). The study was conducted in children and
adolescents (2 to 18 years of age). Hungarian cost vectors were
calculated by linking severity of disease as deﬁned by Investiga-
tor’s Global Assessment (IGA) to average resource use. Resource
use was multiplied by drug costs and unit costs as published in
ofﬁcial databases. RESULTS: Pimecrolimus treatment has an
